Quick Answer
Dogwood Therapeutics, Inc. reported Stockholders Equity of $74.90 million for fiscal year 2025.
Dogwood Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $74.90M | +839.8% |
| 2024 | -$10.12M | -365.9% |
| 2023 | $3.81M | -48.0% |
| 2022 | $7.33M | -49.5% |
| 2021 | $14.50M | -51.6% |
| 2020 | $29.94M | +696.7% |
| 2019 | -$5.02M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $7.26M | +664.5% | +5.5% |
| June 30, 2025 | $6.88M | +119.4% | -2.9% |
| March 31, 2025 | $7.09M | +167.0% | +170.0% |
| December 31, 2024 | -$10.12M | -365.9% | -1166.4% |
| September 30, 2024 | $949.4K | -80.1% | -69.7% |
| June 30, 2024 | $3.14M | -33.2% | +18.1% |
| March 31, 2024 | $2.65M | -55.5% | -30.3% |
| December 31, 2023 | $3.81M | -48.0% | -20.1% |
- Dogwood Therapeutics, Inc. showed an increase of +839.8% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, Dogwood Therapeutics, Inc.’s stockholders equity has grown by 1592.7% (from -$5.02 million to $74.90 million).
- The most recent figure is from Dogwood Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: